Pulmonary Cell News Volume 3.46 | Nov 27 2014

The Environment of Mycobacterium avium subsp. hominissuis Microaggregates Induces the Synthesis of Small Proteins Associated with Efficient Infection of the Respiratory Epithelial Cells
When expressed in non-invasive M. smegmatis, microaggregate binding protein-1 (MBP-1) increased the ability of the bacteria to bind to HEp-2 epithelial cells. Using anti-MBP-1 immune serum, microaggregate binding to HEp-2 cells was significantly reduced. [Infect Immun] Abstract

Efficient Intratracheal Delivery of Airway Epithelial Cells in Mice and Pigs
Researchers aimed to establish a simple method for evaluating cell retention in lungs, and to develop reproducible approaches for efficient cell delivery into mouse and pig lungs. Human lung epithelial cells including normal human bronchial/tracheal epithelial cells and human lung epithelial cell line A549 were infected with pSicoR-GFP lentivirus. [Am J Physiol Lung Cell Mol Physiol] Abstract

Alveolar Type II Epithelial Cell Dysfunction in Rat Experimental Hepatopulmonary Syndrome (HPS)
Scientists evaluated the alveolar epithelial compartment and particularly alveolar type II epithelial cells (AT2) cells in experimental HPS induced by common bile duct ligation (CBDL). They found a significant reduction in pulmonary surfactant protein production associated with increased apoptosis in AT2 cells after CBDL relative to controls. [PLoS One] Full Article

Cell Cycle Synchronization Reveals Greater G2/M-Phase Accumulation of Lung Epithelial Cells Exposed to Titanium Dioxide Nanoparticles
Researchers hypothesized that synchronization after TiO₂ nanoparticle (NP) exposure could reveal dissimilar cell cycle progression when compared with unsynchronized cell population. To test the hypothesis, they exposed lung epithelial cells to 1 and 10 μg/cm² TiO₂ NPs for seven days and one population was synchronized by serum starvation and inhibition of ribonucleotide reductase using hydroxyurea. [Environ Sci Pollut Res Int] Abstract

Sirtuin 1 Activator SRT1720 Protects against Lung Injury via Reduction of Type II Alveolar Epithelial Cells Apoptosis in Emphysema
Researchers investigated whether SRT1720, a pharmacological sirtuin1 activator, could protect against type II alveolar epithelial cells apoptosis in rats with emphysema caused by cigarette smoke exposure and intratracheal lipopolysaccharide instillation in vivo. [COPD] Abstract

LUNG CANCER

CUL4A Overexpression Enhances Lung Tumor Growth and Sensitizes Lung Cancer Cells to Erlotinib via Transcriptional Regulation of EGFR
Growth capacity of lung cancer cells was measured by MTT in vitro and tumorigenesis in vivo, respectively. Scientists found that CUL4A was highly expressed in human lung cancer tissues and lung cancer cell lines, and this elevated expression positively correlated with disease progression and prognosis. [Mol Cancer] Full Article

Active Targeting Docetaxel-PLA Nanoparticles Eradicate the Circulating Lung Cancer Stem Like Cells and Inhibit the Liver Metastasis
Scientists aimed to establish a cancer stem cells (CSCs)-targeting polylactic acid (PLA) encapsulated docetaxel nanoparticles for anti-metastatic therapy. Cyclic binding peptides were screened on CSCs in vitro and the peptide CVKTPAQSC exhibiting high specific binding ability to pulmonary adenocarcinoma tissue was subsequently conjugated to the nanoparticles loaded with docetaxel. [Mol Pharm] Abstract

Methylation-Induced Down-Regulation of TFPI-2 Causes TMPRSS4 Overexpression and Contributes to Oncogenesis in a Subset of NSCLC
In contrast to transmembrane protease, serine 4 (TMPRSS4), tissue factor pathway inhibitor 2 (TFPI-2) expression was down-regulated in non-small cell lung cancer (NSCLC) samples. The in vitro induction of TFPI-2 in lung cancer cell lines decreased the expression of TMPRSS4 mRNA levels. [Cancer Sci] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.

Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (Nivolumab) and FPA008 in Six Tumor Types
Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo, Bristol-Myers Squibb’s investigational programmed death-1 immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor. [Bristol-Myers Squibb Company] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the pulmonary cell community.

NEW Postdoctoral Research Associate – Lung and Vascular Biology (University of Illinois Chicago College of Medicine)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Associate Professor – Physiology (University of Bergen)

Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Research Scientist – Cancer and Inflammatory Diseases (Qu Biologics Inc.)

PhD Students – Heart and Lung Research (Max Planck Institute for Heart and Lung Research)

Postdoctoral Research Fellow – Lung Pathophysiology (Brigham & Women’s Hospital – Harvard Medical School)

PhD Positions – Cardiovascular-Pulmonary Science (Chonbuk National University)

Postdoctoral Researcher – Metabolomics of Pulmonary Medicine (Karolinska Institute)

Scientist – Pluripotent Stem Cell Biology Endoderm Lineages (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.